Other substances

A_BR18

An arbidol analogue.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

A_BR18 is an arbidol analogue predicted to interact with the SARS-CoV-2 spike protein amino acid residues responsible for interaction with ACE2, furin, and TMPRSS2 and also to inhibit the SARS-CoV-2 3C-like protease (Choudhary et al., 2020).

 

BrC1=C(O[H])C(=C2C(=C1)[N](C(=C2C(OCC)=O)CSC3=CC=CC=C3)C)CCN([H])[H]

Supporting references

Link Tested on Impact factor Notes Publication date
Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19
3CLpro ACE2 TMPRSS2 Furin Novel compound Small molecule In silico 		in silico 2.93

Predicted to interact with the SARS-CoV-2 spike protein amino acid residues responsible for interaction with ACE2, furin, and TMPRSS2 and also to inhibit the SARS-CoV-2 3C-like protease.

 Aug/23/2020
Export (.csv)